FGFR2 is a receptor tyrosine kinase activated upon binding of the FGF ligand, which activates RAS-MAPK and PI3K-AKT pathways. Altered function of FGFR2 in cancer may lead to increased cell proliferation and decreased apoptosis. FGFR2 simple variants are seen in about 1% of all tumors, including 8% of uterine cancers, 5% of skin cancers, and 2% of colorectal cancers. Preclinical studies have also shown activity in uterine and breast tumors.